血浆激肽释放酶抑制剂作为糖尿病性黄斑水肿、视网膜静脉阻塞、遗传性血管性水肿及其他相关疾病的潜在治疗方法。
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
Abstract
The invention in this patent application relates to ()-spiro[benzo[][1,3]oxazine-4,3'-pyrrolidin]-2(1)-one derivatives, represented generally by formula 1. These compounds are selective plasma kallikrein inhibitors and may potentially be beneficial in the treatment of several diseases and disorders, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.
摘要
本专利申请中的发明涉及通式1一般表示的（）-螺[苯并[][1,3]恶嗪-4,3'-吡咯烷]-2(1)-酮衍生物。这些化合物是选择性血浆激肽释放酶抑制剂，可能对治疗多种疾病和病症有益，包括遗传性血管性水肿、葡萄膜炎、后葡萄膜炎、湿性年龄相关性黄斑变性、糖尿病性黄斑水肿、糖尿病性视网膜病变和视网膜静脉阻塞。
相似文献
1
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.血浆激肽释放酶抑制剂作为糖尿病性黄斑水肿、视网膜静脉阻塞、遗传性血管性水肿及其他相关疾病的潜在治疗方法。
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
2
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2023 Oct 19;14(11):1491-1492. doi: 10.1021/acsmedchemlett.3c00441. eCollection 2023 Nov 9.
3
Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?血管性疾病所致黄斑水肿抗 VEGF 治疗第 1 天的结果与长期结局之间是否存在关联？
Arq Bras Oftalmol. 2023 Oct 20;87(6):e20220228. doi: 10.5935/0004-2749.2022-0228. eCollection 2023.
4
Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis.年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞的玻璃体附着：系统评价和荟萃分析。
Retina. 2013 Jun;33(6):1099-108. doi: 10.1097/IAE.0b013e31828991d6.
5
Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion.玻璃体内注射贝伐单抗治疗糖尿病性视网膜病变和视网膜静脉阻塞所致黄斑水肿的短期疗效
Int Ophthalmol. 2009 Oct;29(5):343-8. doi: 10.1007/s10792-008-9242-2. Epub 2008 Jun 14.
6
7
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2022 Mar 4;13(4):528-529. doi: 10.1021/acsmedchemlett.2c00085. eCollection 2022 Apr 14.
8
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2022 May 13;13(6):883-884. doi: 10.1021/acsmedchemlett.2c00193. eCollection 2022 Jun 9.
9
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂。
ACS Med Chem Lett. 2022 Jul 29;13(8):1217-1218. doi: 10.1021/acsmedchemlett.2c00323. eCollection 2022 Aug 11.
10
Evolution of intravitreal therapy for retinal and macular disorders.视网膜和黄斑疾病玻璃体内治疗的进展
J Int Med Res. 2020 Jan;48(1):300060518771411. doi: 10.1177/0300060518771411. Epub 2018 May 4.
本文引用的文献
1
Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.回顾遗传性血管性水肿C1抑制剂预防的临床考量及指南建议。
Clin Transl Allergy. 2022 Jan 18;12(1):e12092. doi: 10.1002/clt2.12092. eCollection 2022 Jan.
2
Treatment of Hereditary Angioedema.遗传性血管性水肿的治疗。
J Investig Allergol Clin Immunol. 2021 Feb;31(1):1-16. doi: 10.18176/jiaci.0653.
3
Discovery and development of plasma kallikrein inhibitors for multiple diseases.多种疾病的血浆激肽释放酶抑制剂的发现和开发。
Eur J Med Chem. 2020 Mar 15;190:112137. doi: 10.1016/j.ejmech.2020.112137. Epub 2020 Feb 10.
4
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.用于治疗糖尿病性黄斑水肿的研究性血浆激肽释放酶抑制剂：专家评估。
Expert Opin Investig Drugs. 2020 Mar;29(3):237-244. doi: 10.1080/13543784.2020.1723078. Epub 2020 Jan 31.
Zotero 插件